See All Slides - tctmd.com

Slides

Presentation Cell Therapy 2013

Cardiac-derived Stem Cells Post-MI: CADUCEUS and ALLSTAR

Presenter: Eduardo Marb?n

January 22, 2013

Presentation Cell Therapy 2013

EXCELLENT Trial Design

Presenter: J?r?me Roncalli

January 22, 2013

Presentation Cell Therapy 2013

STEM-AMI trial: cMRI and other observations at 3 years

Presenter: Giulio Pompilio

January 22, 2013

Presentation Cell Therapy 2013

Clinical Outcomes and Surrogate Efficacy Data for a Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells (Revascor™) in Patients With Chronic Heart Failure of Ischemic or Nonischem

Presenter: Kenneth M. Borow

January 22, 2013

Presentation Cell Therapy 2013

AMR-001 Phase 1 Outcome and PreSERVE Study Design: Autologous CD34+ Cells

Presenter: Jonathan Sackner-Bernstein

January 22, 2013

Presentation Cell Therapy 2013

MPC's for Ischemic and Nonischemic Heart Failure

Presenter: Emerson C. Perin

January 22, 2013

Presentation Cell Therapy 2013

SDF-1: Final Results of a Phase 1 Trial and Status of STOP-HF Study

Presenter: Marc S. Penn

January 22, 2013

Presentation Cell Therapy 2013

Swiss AMI Study: Long-term Findings

Presenter: Daniel S?rder

January 22, 2013

Presentation Cell Therapy 2013

Clinical Outcomes and Surrogate Efficacy Data for a Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells

Presenter: Kenneth Borow

January 22, 2013

Presentation Cell Therapy 2013

CD-34+ Cells for Ischemic Heart Failure

Presenter: Bojan Vrtovec

January 22, 2013

Advertisement

Slides

Cardiac-derived Stem Cells Post-MI: CADUCEUS and ALLSTAR

EXCELLENT Trial Design

STEM-AMI trial: cMRI and other observations at 3 years

Clinical Outcomes and Surrogate Efficacy Data for a Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells (Revascor™) in Patients With Chronic Heart Failure of Ischemic or Nonischem

AMR-001 Phase 1 Outcome and PreSERVE Study Design: Autologous CD34+ Cells

MPC's for Ischemic and Nonischemic Heart Failure

SDF-1: Final Results of a Phase 1 Trial and Status of STOP-HF Study

Swiss AMI Study: Long-term Findings

Clinical Outcomes and Surrogate Efficacy Data for a Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells

CD-34+ Cells for Ischemic Heart Failure

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content